LeMaitre Vascular Inc (LMAT) Shares Sold by Epoch Investment Partners Inc.

Share on StockTwits

Epoch Investment Partners Inc. decreased its holdings in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 52.7% in the 4th quarter, HoldingsChannel reports. The fund owned 394,329 shares of the medical instruments supplier’s stock after selling 439,664 shares during the period. Epoch Investment Partners Inc.’s holdings in LeMaitre Vascular were worth $9,322,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of LMAT. Bank of New York Mellon Corp lifted its position in LeMaitre Vascular by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 246,444 shares of the medical instruments supplier’s stock valued at $8,251,000 after purchasing an additional 7,177 shares during the period. First Trust Advisors LP purchased a new position in LeMaitre Vascular in the third quarter valued at about $214,000. Russell Investments Group Ltd. increased its holdings in LeMaitre Vascular by 21.6% in the third quarter. Russell Investments Group Ltd. now owns 177,533 shares of the medical instruments supplier’s stock valued at $6,877,000 after buying an additional 31,575 shares in the last quarter. Victory Capital Management Inc. increased its holdings in LeMaitre Vascular by 62.6% in the third quarter. Victory Capital Management Inc. now owns 9,564 shares of the medical instruments supplier’s stock valued at $371,000 after buying an additional 3,681 shares in the last quarter. Finally, Wells Fargo & Company MN increased its holdings in LeMaitre Vascular by 51.8% in the third quarter. Wells Fargo & Company MN now owns 220,289 shares of the medical instruments supplier’s stock valued at $8,533,000 after buying an additional 75,165 shares in the last quarter. 76.71% of the stock is owned by hedge funds and other institutional investors.

Shares of LeMaitre Vascular stock opened at $30.42 on Friday. LeMaitre Vascular Inc has a 12-month low of $21.79 and a 12-month high of $41.28. The stock has a market capitalization of $588.62 million, a price-to-earnings ratio of 36.21, a P/E/G ratio of 2.98 and a beta of 1.15.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, February 19th. The medical instruments supplier reported $0.24 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.24. LeMaitre Vascular had a net margin of 21.73% and a return on equity of 17.71%. The business had revenue of $28.39 million during the quarter, compared to analysts’ expectations of $26.06 million. As a group, equities research analysts anticipate that LeMaitre Vascular Inc will post 0.84 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 22nd will be paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.12%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.07. The ex-dividend date is Thursday, March 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 33.33%.

In other news, insider Trent G. Kamke sold 16,604 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $29.63, for a total transaction of $491,976.52. Following the completion of the transaction, the insider now directly owns 19,857 shares of the company’s stock, valued at approximately $588,362.91. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 20.30% of the company’s stock.

A number of brokerages have issued reports on LMAT. BidaskClub raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a report on Thursday, February 21st. ValuEngine raised shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Lake Street Capital increased their target price on shares of LeMaitre Vascular to $27.00 and gave the company a “hold” rating in a report on Wednesday, February 20th. Finally, Zacks Investment Research cut shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $33.29.

TRADEMARK VIOLATION WARNING: “LeMaitre Vascular Inc (LMAT) Shares Sold by Epoch Investment Partners Inc.” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://weekherald.com/2019/03/15/lemaitre-vascular-inc-lmat-shares-sold-by-epoch-investment-partners-inc.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Story: What does EPS mean?

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.